age [years] | median (range) | 61 (33–84) | |
---|---|---|---|
total | n = 151 | 100 % | |
primary tumor | non-small cell lung cancer | 70 | 46 |
small-cell lung cancer | 20 | 13 | |
melanoma | 12 | 8 | |
renal cell carcinoma | 7 | 5 | |
colorectal cancer | 3 | 2 | |
breast cancer | 25 | 17 | |
others | 12 | 8 | |
unknown | 2 | 1 | |
Karnofsky performance score | ≥ 70 | 119 | 79 |
< 70 | 30 | 20 | |
unknown | 2 | 1 | |
RPA classification | 1 | 17 | 11 |
2 | 99 | 66 | |
3 | 33 | 22 | |
unknown | 2 | 1 | |
GPA classification | 0-1.0 | 63 | 43 |
1.5-2.5 | 70 | 48 | |
3.0 | 11 | 7 | |
3.5-4.0 | 3 | 2 | |
unknown | 4 | 3 | |
Barthel index | 90-100 | 115 | 76 |
<90 | 34 | 23 | |
unknown | 2 | 1 | |
fractionation of whole-brain radiotherapy | 10x3 Gy | 80 | 53 |
14x2.5 Gy | 12 | 8 | |
others | 32 | 21 | |
unknown | 5 | 3 | |
fractionation of stereotactic radiotherapy | 1x18-20 Gy | 10 | 7 |
7x5 Gy | 4 | 3 | |
5x6 Gy | 4 | 3 | |
10x4 Gy | 1 | 1 | |
initial steroid dose (prednisone equivalent) | no steroids | 41 | 27 |
daily dose <50 mg | 38 | 25 | |
daily dose 50–100 mg | 38 | 25 | |
daily dose >100 mg | 26 | 17 | |
unknown | 8 | 5 | |
extracranial tumor status | primary tumor (PT) not detectable | 54 | 36 |
PT detectable, not progressive | 44 | 29 | |
PT progressive | 48 | 32 | |
PT status unknown | 5 | 3 | |
any extracranial metastases | 104 | 70 | |
intracranial tumor status | >3 metastases | 83 | 56 |
1-3 metastases | 65 | 44 | |
number of metastases unknown | 4 | 3 | |
largest metastasis >2 cm | 53 | 35 | |
diameter of metastases unknown | 17 | 12 |